Published on 17 Jan 2022 on Zacks via Yahoo Finance

Medtronic's (MDT) DTM SCS Endurance Therapy Study Data Positive

Medtronic plc MDT recently announced three-month favorable results from an on-label, prospective, multi-center study showing meaningful pain relief using DTM SCS endurance therapy. Notably, DTM SCS endurance therapy is a modified, lower-energy variation of the company's Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain.

Modeling based on actual three-month data demonstrates that DTM SCS endurance therapy allows 5.5-7.5 years of device longevity when programmed on the Vanta recharge-free neurostimulator. DTM SCS endurance therapy allows long-lasting recharge-free performance on Vanta and 5-minute recharge on Intellis neurostimulators.

The recent development is likely to fortify Medtronic’s Neuromodulation business, which is part of its Neuroscience Portfolio.